U.S. Markets open in 15 mins.

Insmed Incorporated (INSM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.07-1.07 (-6.24%)
At close: 4:00PM EDT
People also watch
  • subpart H is accelerated approval and rarely used and
    doesn't cut into the timelines in the few cases ever used.Agree all these breakthru etc designations have done nothing to advance arikayce outside of the normal path to approval.
  • IdiotInvestorvillage bd FAKE NEWS ! zake1".Maybe we will see a Sub Part H approval in the next few months, rather than being forced to wait until Sept, or Oct." \Maybe the poor fellow meant 2018\?\dont understand the process \revenues when?\ this is important to have an understanding of submission and review to assess investment timing\approximate review results and revenue timeline has been posted and deleted by those who push Insmed Fake News\idiotvillage STAY THERE!\
  • Sub Part H approval should take 9 months from results with a little luck
  • Options : Open interest in Oct puts at 15 strike price is huge : 4464 (i.e., involving 446,400 shares). In net effect, bets being made that INSM share price will either be above or below $9 at October expiration. (current premium is approx. $6)
  • ouch. breaks down through support levels of April and May lows. shakeout?
  • 10M @$17 would be a nice cushion into results
  • Bought 1000 at the close, $16.09, up after market .24. Don't make this hard folks. Recognize trade opps.
  • Pin the stock game continues ! \ \ Institutional Holdings 91 % ! \Poor fella cant see the forest through the trees\Stay there!
    Cubbies in first place!\ historian all over the Short interest \The idiot investor village board went from "We dont need Money!\Someone will buy us! \to\Offering\ ! Partnership \ ! Its really just 6 people who view 12 times a day \
    PS- see where they are going? We have a price for the offering\
  • Yesterdays ASM was everything management could ask for No one was there.
    Approved the Insmed Incorporated 2017 Incentive Plan.Management basically gets tons of shares for NOTHING
    Will shareholders get sold down the drain while a few make tons of money?
    Lewis is a former business manager not a scientist educator or doctor.Lewis will take a promotion to a big pharma with the deal.Hes just biding his time
  • 2 mos ago I sold my 8 month long position\ ($17.67- entry 998) for a 108% profit (+4 swing trades).\Last week Terryinsm called the offering price and the swing trade\.I can not post it but I will be a buyer of the offering \- should there be one.It will not be a long it will be a trade.\
  • Aridigm sues Insmeds patents = LEGAL PROCEEDINGS
    On May 1, 2017, the Company filed a post grant review, or a PGR, petition in the United States Patent and Trademark Office Patent Trial and Appeal Board, or PTAB, challenging the validity of all 26 claims of U.S. Patent No.9,402,845 or the ‘845 Patent, assigned to Insmed Incorporated, or Insmed. The ‘845 Patent issued on August 2, 2016, and is entitled “Lipoid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof.”
    PGR is a proceeding that became available in September 2012 in accordance with the America Invents Act. In a PGR, a petitioner may request that PTAB reconsider the validity of issued patent claims. Any patent claim PTAB determines to be unpatentable is stricken from the challenged patent.
    Once PTAB assigns a filing date to the Company’s PGR petition, Insmed will have 3 months to file an optional Preliminary Response. Then, within 3 months of Insmed’s Preliminary Response due date, PTAB will decide whether to institute post grant review of the ‘845 Patent. If the PGR is instituted, PTAB should issue a Final Written Decision addressing validity of patent claim(s) within 18 months of the filing date.
  • waiting for below $16 to buy
    $15.40 would be the bomb
    Trump slump underway
  • Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the appointment of Paolo Tombesi as Chief Financial Officer, effective June 1, 2017, and Paul Streck, M.D., as Chief Medical Officer, effective June 5, 2017. Additionally, Eugene Sullivan, M.D., has been appointed to the newly created role of Chief Product Strategy Officer.
  • \ from the 10Q\The Parent is no longer developing the Iplex product, and has no present intention of resuming such development. " \
    doesnt matter to the Idiot village board\
  • Insmed holding up better than all biotechs.by just staying even
  • I sure am glad I did not listen to the basher Terry at $7. I am up over 130%
  • good company ,good team it will come back
  • It is time to face the truth. This is stock is WINNING.
  • Attention all bagholders.........you are all losers. BK within 2 years!!!! INSM was $29 two years ago......a total criminal fraud!!!!!!!! SELLLLLL!